Pulmotect Inc.
Synthetic inhaled drug prevents pneumonia in cancer patients
This article was originally published in Start Up
Executive Summary
Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.
You may also be interested in...
Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
US Health And Wellness Launches: Perrigo, Lightbody, Nature’s Bounty, PLT, Healthycell, More
Nicotine mint lozenge approval for Perrigo; Lightbody for digital vision health; PLT has broad-spectrum immune health ingredient; Souvenaid for stronger synapses; Kinesiology tape for cellular oxygenation; Healthycell joint health and mobility gel; Nature’s Bounty Optimal Solutions hair, metabolism supplements; and Perricone extends vitamin c ester line.
US Dietary Ingredient ‘Preclusion’ Swings On Information Closed To Supplement Industry – CRN
Trade group contends FDA’s misuse of regulation prohibiting any substance studied or approved as a drug in US from being used as dietary ingredients undermines innovation in supplement industry and is detrimental to consumer choice and health.